Answers are grounded in this paper and cite their sources.
Retrospective analysis shows reduced TRJV following red blood cell exchange in adults with sickle cell disease, indicating cardiovascular benefits.
To the Editor, Pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) are well-described comorbidities in sickle cell disease (SCD), and PH is an independent predictor of mortality in SCD.1 While the exact pathophysiology of PH and HFpEF development in SCD is unknown, contributing factors include left ventricular remodelling from chronic anaemia, haemolysis-induced pulmonary vasoconstriction and chronic thromboemboli.2 Although the gold standard for diagnosing PH is right heart catheterization (RHC), Doppler-derived tricuspid regurgitant jet velocity (TRJV) is a less invasive tool to estimate the pulmonary artery pressure (PAP). A TRJV ≥2.5 m/s has been shown to be independently associated with mortality in SCD patients, irrespective of confirmation by RHC.3 Chronic red blood cell exchange (RCE) has been suggested by experts for patients with elevated TRJV.4, 5 Diluting the circulating concentration of HbS-containing red blood cells could reduce the risk of events due to intravascular haemolysis and vaso-occlusion, like acute chest syndromes.2, 5 However, evidence supporting RCE specifically for PH and cardiac remodelling remains limited.6-9 The Centre hospitalier de l'Université de Montréal (CHUM) is a reference centre for adults with SCD, many of whom are managed with regular RCE. To further our understanding of the impact of RCE on cardiopulmonary function, we conducted this retrospective study to describe longitudinal changes in echocardiographic parameters in individuals with SCD while on RCE, regardless of indication. The primary objective was to describe the change in TRJV after at least 3 months of RCE (to include a minimum of two procedures), hypothesizing that TRJV would decrease after initiation of RCE. We defined a priori two subgroups based on baseline TRJV: elevated TRJV defined as ≥2.5 m/s (Group 1) versus non-elevated TRJV (<2.5 m/s; Group 2). Secondary objectives included a stratified analysis based on baseline TRJV, identifying predictors of elevated (>2.5 m/s) TRJV at baseline, as well as predictors of TRJV response to RCE, and exploring the impact of RCE on parameters of left ventricle (LV) function. See Appendix S1 for details regarding methods and statistical considerations. A total of 105 patients with SCD undergoing RCE were screened for analysis. Of these, 40 patients were excluded because there were less than two transthoracic echocardiogram (TTE) performed and 25 patients were excluded because TTE were not within the timeframes set out in the methods (Appendix S1). Therefore, 40 patients were eligible for inclusion (20 females and 20 males; Table 1) with a genotype distribution of 57.5% HbSS/Sβ0, 32.5% HbSC and 10.0% HbSβ+. The most common indication for RCE was elevated TRJV (≥2.5 m/s at rest) and/or suspected PH based on echocardiography (n = 28). Other non-mutually exclusive indications for RCE included neurological complications (n = 14), recurrent vaso-occlusive events (n = 10), recurrent priapism, leg ulcers, nephropathy, hepatic sequestration and progressive avascular necrosis despite hydroxycarbamide (hydroxyurea). Of the 18 individuals taking hydroxycarbamide at baseline, 15 stopped upon transitioning to RCE, while the remaining three continued the medication throughout the period of the study. Baseline resting TRJV was evaluable for 36 (90%) patients: The mean value was 2.59 m/s, and there was no difference between genotypes (p = 0.25). Twenty-four patients (66.7%; Group 1) had elevated (≥2.5 m/s) TRJV, while the remaining 12 (33.3%) had non-elevated TRJV (Group 2; <2.5 m/s). Most clinical and laboratory characteristics were not significantly different between TRJV subgroups, including age, sex, alpha-thalassaemia and glucose-6-phosphate dehydrogenase status as well as Hb, HbF% and markers of haemolysis. Group 1 (elevated TRJV) patients had slightly higher systolic blood pressure at the time of first TTE (123 vs. 111 mmHg, p = 0.0454) and a numerically higher proportion of HbSS/Sβ0 (58.3% vs. 50.0%, p = 0.18). At follow-up, the mean haematocrit and platelet count increased (p = 0.0049; p = 0.0050 respectively), while the fraction of HbF and Hb variant (S or S+C) decreased (p = 0.0024; p < 0.0001 respectively), as expected with exchange transfusions (Table 2). Baseline TTE was performed prior to the initiation of RCE in 31 (77.5%) patients, and a median of 6 days following a first RCE in the remaining 9 (22.5%) patients. Left ventricular end diastolic diameter (LVEDD) or left ventricular mass index (LVMI) was normal in all patients. All patients had a baseline left ventricular ejection fraction (LVEF) >50% except one who had LVEF <35% secondary to viral myocarditis. At baseline, one patient (2.5%) had grade 3 diastolic dysfunction, one (2.5%) patient had grade 2 diastolic dysfunction, 18 (46.1%) had grade 0 diastolic dysfunction and 19 (48.7%) had indeterminate diastolic dysfunction. The median time on RCE at the time of follow-up TTE was 15 months (interquartile range [IQR] 10–26). A median of 10 procedures (range: 3–39) with a mean interval of 6.5 weeks (range: 4–10) was performed between TTE. The average TRJV was significantly reduced (2.59 m/s pre-RCE vs. 2.43 m/s post-RCE, p = 0.0255) (Figure 1A), and the proportion of patients with elevated TRJV decreased from 66.7% to 33.3% during follow-up (p = 0.0098). Cardiac diameters (LVEDD, LVMI, left atrial volume index [LAVI]), LVEF and diastolic function parameters were not different upon reassessment in the overall cohort. The patients with grade 2 and 3 diastolic dysfunction at baseline had indeterminate diastolic dysfunction at follow-up. One patient (2.5%) had grade 2 diastolic dysfunction at follow-up with a previous indeterminate diastolic dysfunction. The improvement in TRJV was primarily driven by Group 1 (TRJV ≥2.5 m/s) patients who showed a significant reduction in TRJV (TRJV 2.80 m/s pre-RCE vs. 2.45 m/s post-RCE, p < 0.001) and mean systolic PAP (36 mmHg pre vs. 28 mmHg post, p < 0.0001) at follow-up (Figure 1B). Almost all patients (92%) either improved or stabilized their TRJV at follow-up in this subgroup, as opposed to 25% in Group 2 (p < 0.0001). Despite a numerical increase in the TRJV from 2.19 m/s pre-RCE to 2.38 m/s post-RCE in the latter group (p = 0.07), 83% of Group 2 patients still had a TRJV <2.5 m/s at follow-up, while 16.6% (2/12) of Group 2 patients showed an increased TRJV. The difference in ∆TRJV between the two groups was statistically significant (p < 0.0001), suggesting a differential effect of RCE by subgroup. We tested the association between the TRJV trajectory (∆TRJV) and markers of interest for the whole cohort and by subgroup. ∆TRJV was not associated with either genotype or hydroxycarbamide treatment (univariate analysis). Haemoglobin, lactate dehydrogenase, total bilirubin and ferritin, all at baseline and ∆ values (see Appendix S1), did not correlate with ∆TRJV in univariate analyses, nor did age, weight, time on RCE or mean pre-transfusion Hb variant %. Patients without macroalbuminuria between TTE tended to have better TRJV improvement over time (−0.26 vs. +0.16, p = 0.0325), and this effect was more pronounced among Group 1 patients (−0.43 vs. +0.11, p = 0.0089). On multivariable regression analysis, a higher baseline TRJV value (p < 0.0001) and male sex (p = 0.03) were associated with a greater TRJV improvement in the overall cohort, with a trend for higher weight (p = 0.08). In contrast, the presence of macroalbuminuria while undergoing RCE was significantly associated with a TRJV increase (p = 0.0011). In addition, there was a significant interaction between age and sex; older women were more likely to experience TRJV worsening (p = 0.03) (Table S1). Among Group 1 patients, a higher baseline TRJV (p < 0.0001) was significantly associated with a decrease in TRJV at follow-up, as opposed to older age (p = 0.0479) and the presence of macroalbuminuria (p < 0.0001) (Table S2). The long-term consequences of RCE on PAP, LV function and functional capacity in SCD are not well understood. In our study, 36 adults with SCD on RCE for various indications demonstrated improvement in TRJV after a median of 10 procedures, primarily driven by a significant decrease among those patients with elevated baseline TRJV. In contrast, cardiac diameters and left ventricular function parameters were not statistically different at follow-up. Our findings are consistent with previous work reporting an improvement in the TRJV by ultrasound after initiating RCEs.9-11 To our knowledge, however, ours is the first study to include patients with HbSC and HbSβ+ genotypes. Although there is no data on optimal Hb variant targets for suspected PH, our pre-transfusion Hb variant % (44 ± 16%) at the time of follow-up TTE was higher than our predefined and conventional target of <30%. This might account for the relatively modest TRJV improvement. Furthermore, there was no significant correlation between ∆Hb with RCE and ∆TRJV in all the analyses, despite a mean Hb increase of 15 g/L. This suggests that the improvement in TRJV following chronic RCE initiation is explained by mechanisms other than normalization of Hb in our cohort, which contrasts with paediatric studies where TRJV was strongly influenced by anaemia severity.10 With a baseline Hb of 9.7 g/L and a third of subjects being composite heterozygotes (HbSC or HbS/β+), it is possible that our sample represents a subset of patients with less severe anaemia and haemolysis than previous cohorts. Optimal post-procedure Hb targets have yet to be established, and institutional practices still vary greatly.11-14 Our results suggest that patients with SCD and a TRJV ≥2.5 m/s may benefit from RCE irrespective of its effects on total Hb and that younger age may be a marker of responsiveness. Larger prospective studies are required to confirm these findings in patients with RHC-confirmed PH.15 Future investigations should also determine whether observed improvements in TRJV and haemodynamics persist over time and their correlation with clinical outcomes.15 JM-R, RB, SF and BJP designed the study. JM-R, RB, M-CB and AS collected and validated the data. JMR and RB performed the statistical analyses. All authors participated in the interpretation of data, writing and editing of the manuscript. We thank Dre Andréanne Morin, PhD, for her input in statistical analysis. The authors have no conflicts of interest to disclose. Dr. Brian J. Potter is supported by a Fonds de recherche Québec- Santé (FRQS) clinician–scientist career award (267436). The study received approval by the institutional review boards of the Centre de Recherche du CHUM (CRCHUM) and was conducted in compliance with the Declaration of Helsinki (2024-11851, 23.193). Appendix S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Mercier‐Ross et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: